Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sumatriptan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sumatriptan Succinate tablets 100 mg | EXPERIMENTAL | Sumatriptan Succinate tablets 100 mg of Dr.Reddy's Laboratories Limited |
| Imitrex 100 mg Tablets | ACTIVE_COMPARATOR | Imitrex 100 mg Tablets of Glaxosmithkline |
| Name | Type | Description |
|---|---|---|
| Sumatriptan | DRUG | Sumatriptan Succinate Tablets 100 mg |
Inclusion Criteria: 1. The subjects should be healthy males between 18 and 45 years. 2. The subjects should be screened within 21 days prior to the administration of first dose of the study.. 3. The subjects should have a BMI between 18 and 25 kg/m2 4. The subjects should be able to communicate eff...
Sumatriptan is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed bioequivalence study evaluating Sumatriptan Succinate Tablets 100 mg under fed conditions.
Sumatriptan is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY.
Sumatriptan is in Phase 1 clinical development. One Phase 1 trial has been completed, and there are no active trials currently ongoing.
Sumatriptan has one completed clinical trial, NCT01269281, titled 'Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions'. This Phase 1 study enrolled 50 healthy male participants in India.
Sumatriptan is an investigational drug currently in Phase 1 clinical development. It has not been approved by the FDA, as it is still undergoing clinical trials.
Sumatriptan is a small molecule drug. Its specific molecular target has not been disclosed in the available clinical trial information.